Calithera Biosciences Inc. (CALA) Stock Price Down 3.5%
Calithera Biosciences Inc. (NASDAQ:CALA) shares fell 3.5% on Thursday . The company traded as low as $3.27 and last traded at $3.29, with a volume of 184,732 shares trading hands. The stock had previously closed at $3.41.
A number of research firms have weighed in on CALA. Zacks Investment Research upgraded shares of Calithera Biosciences from a “hold” rating to a “buy” rating and set a $6.50 target price on the stock in a research note on Tuesday, March 22nd. JMP Securities reiterated a “buy” rating on shares of Calithera Biosciences in a research note on Wednesday, June 8th. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Calithera Biosciences in a research note on Thursday, May 12th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $10.48.
The company’s 50 day moving average price is $4.36 and its 200 day moving average price is $5.26. The firm’s market cap is $65.02 million.
Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by $0.05. On average, equities analysts predict that Calithera Biosciences Inc. will post ($2.15) earnings per share for the current fiscal year.
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.